Reports on the merger between Paris, France-based Valigene and Newtown, Pennsylvania-based Kimeragen Inc. to create a functional genomic company, Veligen. Comments of Jean Louis Pourny, chief executive officer of Valigene on the merger; Several research work to carried in Valigen; Other developmental plans of the Valegene.